Sofinnova Investments’s Coherus Oncology CHRS Stock Holding History

Sofinnova Investments’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-434,555	Closed	-$6.01M	–	76
2021 Q2	$6.01M	Hold	434,555	–	–	0.35%	46
2021 Q1	$6.35M	Hold	434,555	–	–	0.38%	45
2020 Q4	$7.55M	Hold	434,555	–	–	0.45%	42
2020 Q3	$7.97M	Sell	434,555 -1,498,666	-78%	-$27.9M	0.59%	29
2020 Q2	$34.5M	Hold	1,933,221	–	–	2.18%	11
2020 Q1	$31.4M	Hold	1,933,221	–	–	2.9%	8
2019 Q4	$34.8M	Hold	1,933,221	–	–	2.51%	10
2019 Q3	$39.2M	Sell	1,933,221 -160,000	-8%	-$3.2M	3.54%	9
2019 Q2	$46.3M	Sell	2,093,221 -775,000	-27%	-$13.5M	4.25%	8
2019 Q1	$39.1M	Hold	2,868,221	–	–	3.77%	9
2018 Q4	$26M	Hold	2,868,221	–	–	3.23%	10
2018 Q3	$47.3M	Sell	2,868,221 -25,000	-0.9%	-$443K	4.22%	8
2018 Q2	$40.5M	Hold	2,893,221	–	–	4.59%	6
2018 Q1	$32M	Buy	+2,893,221	New	+$31.7M	5.49%	7

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sofinnova Investments's CHRS Position: Q3 2021 in Review

Sofinnova Investments sold out of Coherus Oncology (CHRS) in Q3 2021, closing a stake of 434,555 shares — an estimated $6.01M sold.

Sofinnova Investments first reported a position in CHRS in Q1 2018 and held it in 14 quarters. The position peaked at $47.3M in Q3 2018. 187 funds tracked by Wall St. Rank hold CHRS as of Q3 2021.

Sofinnova Investments reported no remaining Coherus Oncology position as of Q3 2021 after selling out during the quarter.
Sofinnova Investments sold 434,555 Coherus Oncology shares in Q3 2021, an estimated $6.01M.
Sofinnova Investments first reported a position in Coherus Oncology in Q1 2018 and held it in 14 quarters.
Sofinnova Investments's Coherus Oncology position peaked at $47.3M in Q3 2018.
187 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2021.

Based on Sofinnova Investments's 13F filing for Q3 2021, filed 15 Nov 2021.